英国的研究发现,GLP-1类药物,如Ozempic,在心脏病发作后,通过改善小船的血液流动,可以减少心脏损伤。 GLP-1 drugs like Ozempic may reduce heart damage after heart attacks by improving blood flow in tiny vessels, UK study finds.

GLP-1重力损失药物如Ozempic和Wegovy在心脏病发作后通过防止“不回流”来帮助减少心脏损伤, 英国的一项研究指出, GLP-1 weight-loss drugs like Ozempic and Wegovy may help reduce heart damage after a heart attack by preventing "no-reflow," a condition where tiny heart blood vessels stay blocked despite clearing the main artery, according to a UK study. 在老鼠模型中,药物通过激活钾渠道、改善输血流向受损组织的情况,放松了在氧气流失期间使容器收缩的细胞,改善了血液流向受损组织的情况。 In mouse models, the drugs relaxed pericytes—cells that constrict vessels during oxygen loss—by activating potassium channels, improving blood flow to damaged tissue. 发表在《自然通讯》上的调查结果表明,这些药物可以重新用于改善恢复,甚至可能在紧急情况下由护理人员管理。 The findings, published in Nature Communications, suggest these drugs could be repurposed to improve recovery, possibly even administered by paramedics during emergencies. 先前的研究显示,GLP-1药物与体重损失无关,心血管风险降低,但这一研究提供了一种潜在的机制:加强微血管血液流动。 While prior research showed GLP-1 drugs lower cardiovascular risk independently of weight loss, this study offers a potential mechanism: enhanced microvascular blood flow. 需要进行人类试验,以确认益处并确定最佳利用。 Human trials are needed to confirm benefits and determine best use.